Reports Q1 revenue $32.607M, consensus $46.09M. “The recent FDA approval of Vafseo represents a transformational milestone for Akebia as we initiate launch activities that we believe will enable widespread access and rapid adoption when Vafseo is available in January 2025,” said John P. Butler, Chief Executive Officer of Akebia. “Upon FDA approval of Vafseo, we initiated work to drive demand from potential prescribers and to contract with dialysis providers. We are progressing plans for generating clinical data to identify additional areas of potential benefit to patients as we remain committed to the kidney community. We also expect to engage with the FDA on label expansion opportunities for Vafseo by the end of this year.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Akebia Therapeutics (AKBA) Q1 Earnings Cheat Sheet
- Akebia price target raised to $6 from $5 at H.C. Wainwright
- Largest borrow rate increases among liquid names
- Akebia Therapeutics Celebrates FDA Approval of Anemia Drug